標(biāo)題: Titlebook: Drugs Targeting B-Cells in Autoimmune Diseases; Xavier Bosch,Manuel Ramos-Casals,Munther A Khamash Book 2014 Springer Basel 2014 Cryoglobu [打印本頁] 作者: commotion 時間: 2025-3-21 18:39
書目名稱Drugs Targeting B-Cells in Autoimmune Diseases影響因子(影響力)
書目名稱Drugs Targeting B-Cells in Autoimmune Diseases影響因子(影響力)學(xué)科排名
書目名稱Drugs Targeting B-Cells in Autoimmune Diseases網(wǎng)絡(luò)公開度
書目名稱Drugs Targeting B-Cells in Autoimmune Diseases網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Drugs Targeting B-Cells in Autoimmune Diseases被引頻次
書目名稱Drugs Targeting B-Cells in Autoimmune Diseases被引頻次學(xué)科排名
書目名稱Drugs Targeting B-Cells in Autoimmune Diseases年度引用
書目名稱Drugs Targeting B-Cells in Autoimmune Diseases年度引用學(xué)科排名
書目名稱Drugs Targeting B-Cells in Autoimmune Diseases讀者反饋
書目名稱Drugs Targeting B-Cells in Autoimmune Diseases讀者反饋學(xué)科排名
作者: Tdd526 時間: 2025-3-21 20:57 作者: dendrites 時間: 2025-3-22 04:12 作者: Gerontology 時間: 2025-3-22 07:20 作者: 拘留 時間: 2025-3-22 10:59 作者: Mobile 時間: 2025-3-22 13:23 作者: Mobile 時間: 2025-3-22 17:41 作者: Lasting 時間: 2025-3-22 23:04
Targeting B Cells in ANCA-Associated Vasculitides,mall and medium-sized vessels. Glomerulonephritis in AAV is typified by focal necrosis, crescent formation, and few or no immunoglobulin deposits. In vitro and animal evidence suggests that ANCA play a pathogenic role in AAV. Specific gene expression signatures are reported to predict long-term prog作者: 費(fèi)解 時間: 2025-3-23 03:09 作者: 外向者 時間: 2025-3-23 05:56 作者: 暗指 時間: 2025-3-23 11:07 作者: Cupidity 時間: 2025-3-23 17:06
Targeting B Cells in Neurological Autoimmune Diseases,the activation-dependent release of cytokines and the mutual activation of T cells, B-cell-directed therapy has emerged as a promising tool in the therapeutic strategies of a range of autoimmune neurological diseases, such as multiple sclerosis (MS), neuromyelitis optica, autoimmune encephalitis, ch作者: 火車車輪 時間: 2025-3-23 19:52
Targeting B Cells in Other Systemic Autoimmune Diseases,ditions, evidence on the use of these therapies is restricted to rituximab and it mainly relies on individual case reports or short series. In general, the underlying pathophysiology of the disease and/or the successful use of biological agents with a different mechanism of action seem to justify th作者: 狂怒 時間: 2025-3-24 00:21 作者: ABOUT 時間: 2025-3-24 06:26
The Future Potential of Biosimilars Targeting B-Cells,pire, leaving open the potential for development and regulatory approval of 1 or more “similar” versions of these biologic therapies, termed biosimilars in Europe (BS)—the term that will be used in this chapter—subsequent entry biologics in Canada, or follow-on-biologics in the USA. The development 作者: Exposition 時間: 2025-3-24 10:30
Natural Resource Management and Policyand for therapeutic uses. The initial drive to specifically target B cells was part of the effort to develop more effective and safer therapeutic agents to treat B-cell malignancies. Anti-idiotype antibodies were effective but a different antibody needed to be developed for each patient, contributin作者: right-atrium 時間: 2025-3-24 14:34
Water Development and Poverty Reductionmune disease. The last decade has witnessed substantial growth in the number of therapeutic agents that target B cells themselves, or molecules key to B cell survival or function. In order to understand, develop, and eventually predict the outcomes of B cell targeted therapies, a thorough understati作者: Mediocre 時間: 2025-3-24 17:33
Ryan Hill,Yemi Katerere,Tabeth Matiza-Chiutanoclonal antibody rituximab for the treatment of B cell malignancies and reassurance about the overall safety of B cell depletion, the field of anti-B cell therapies has expanded over the last decade to the treatment of multiple autoimmune diseases. Moreover, growing knowledge of the biology of B ce作者: iodides 時間: 2025-3-24 21:39
?. H. Olcay ünver,Rajiv K. Gupta disease have led to a growing evidence of the importance of B-cells in the origins of the disease. Two main therapeutic approaches targeting B-cells have emerged: one directed against B-cell specific molecules and the other directed against B-cell survival factors. We will discuss below the differe作者: fulcrum 時間: 2025-3-25 01:16 作者: 大火 時間: 2025-3-25 05:25 作者: Vulnerary 時間: 2025-3-25 08:14
Daniel B. Cornfield,Randy Hodsonidisciplinary therapeutic approach. Treatment of sicca manifestations is symptomatic (topical therapies like saliva substitutes and preservative-free artificial tears), while the management of extraglandular features is tailored to the specific organs involved. The use of biological drugs targeting 作者: 矛盾 時間: 2025-3-25 11:59 作者: 拘留 時間: 2025-3-25 17:02
Nadya Araujo Guimar?es,Marcia de Paula Leitedous interest around the role of B-cells in the early inflammation, autoimmunity, and subsequent fibrosis both in animal and human models. There have been promising results from B-cell depletion therapy in clinical trials in both SSc and IIM. This review will concentrate on the role of B-cells in pa作者: 發(fā)出眩目光芒 時間: 2025-3-25 20:31 作者: BLANC 時間: 2025-3-26 02:03 作者: 話 時間: 2025-3-26 07:51 作者: Consequence 時間: 2025-3-26 08:41
Building an International Sociology of Workditions, evidence on the use of these therapies is restricted to rituximab and it mainly relies on individual case reports or short series. In general, the underlying pathophysiology of the disease and/or the successful use of biological agents with a different mechanism of action seem to justify th作者: Assignment 時間: 2025-3-26 16:13
Nadya Araujo Guimar?es,Marcia de Paula Leiteiseases such as SLE. Rituximab also has a longer established role in the treatment of B-cell lymphoproliferative disorders and rheumatoid arthritis. In this chapter we review the available data on the safety aspects of B-cell targeted therapies. A common adverse event with this family of agents is i作者: 牲畜欄 時間: 2025-3-26 18:35
Daniel B. Cornfield,Randy Hodsonpire, leaving open the potential for development and regulatory approval of 1 or more “similar” versions of these biologic therapies, termed biosimilars in Europe (BS)—the term that will be used in this chapter—subsequent entry biologics in Canada, or follow-on-biologics in the USA. The development 作者: 類人猿 時間: 2025-3-26 23:20 作者: 共同生活 時間: 2025-3-27 03:36 作者: Vertebra 時間: 2025-3-27 06:12 作者: meditation 時間: 2025-3-27 13:17 作者: 蒸發(fā) 時間: 2025-3-27 17:00
Daniel B. Cornfield,Randy Hodsonease has long been regarded as very unlikely to be successful. In 2002 the first report was published in a case series of five patients that advocated B cells as a therapeutic target, spurred by a report of Takemura et al., who even suggested that the activation of T cells in the rheumatoid synovium was B cell-dependent.作者: Duodenitis 時間: 2025-3-27 18:49 作者: 矛盾心理 時間: 2025-3-28 00:30 作者: cuticle 時間: 2025-3-28 04:01
Building an International Sociology of Workditions such as steroid-resistant and dependent sarcoidosis, Beh?et disease with retinal vasculitis, chronic hepatitis C virus-associated polyarteritis nodosa, highly active refractory Takayasu arteritis, and Henoch–Sch?nlein purpura nephritis.作者: Outwit 時間: 2025-3-28 06:35
B-Cell Targeted Therapies in Rheumatoid Arthritis,ease has long been regarded as very unlikely to be successful. In 2002 the first report was published in a case series of five patients that advocated B cells as a therapeutic target, spurred by a report of Takemura et al., who even suggested that the activation of T cells in the rheumatoid synovium was B cell-dependent.作者: 蘑菇 時間: 2025-3-28 11:21
,B-Cell Targeted Therapies in Primary Sj?gren Syndrome,the evidence from controlled trials has suggested that tumour necrosis factor blockers are not efficacious in primary SS, the use of B-cell targeted agents (rituximab, epratuzumab, belimumab) may be more promising therapies. However, the potential risks and benefits of these new agents must be always weighted carefully.作者: Injunction 時間: 2025-3-28 14:42
B-Cell Targeted Therapies in Cryoglobulinemia,ntext of these three concomitant biologic events linked one to each other, i.e., chronic infection, autoimmunity, and B-cell lymphoproliferation. Since rituximab is used for B-cell depletion in CV, this drug will be herein discussed.作者: LAY 時間: 2025-3-28 19:37 作者: exquisite 時間: 2025-3-29 00:39
Book 2014 arthritis, systemic lupus erythematosus, Sj?gren syndrome, ANCA-associated vasculitis and cryoglobulinemia. Organ-specific autoimmune diseases are discussed with respect to the use of B-cell directed therapies in neurological autoimmune diseases and autoimmune cytopenias. Situations in which B-cell作者: 粗鄙的人 時間: 2025-3-29 04:49 作者: 怪物 時間: 2025-3-29 07:22
Book 2014ed evidence. The book also offers a valuable reference tool for rheumatologists, internists, nephrologists, immunologists, and all specialists involved in the multidisciplinary care of patients with rheumatic and systemic autoimmune diseases..作者: 陪審團(tuán) 時間: 2025-3-29 15:13 作者: discord 時間: 2025-3-29 17:15
Arne L. Kalleberg,Kevin T. Leichtd trials. Belimumab has been licensed for use in SLE in 2011 by the FDA and European Medicines Agency. Forthcoming years will show the real value of B-cell targeted therapies, including the off-label use of rituximab and especially the licensed use of belimumab, as part of the standard of care in patients with SLE.作者: Malfunction 時間: 2025-3-29 22:24 作者: 包庇 時間: 2025-3-30 00:16 作者: 新奇 時間: 2025-3-30 04:51 作者: 損壞 時間: 2025-3-30 12:04 作者: Glaci冰 時間: 2025-3-30 14:00
B-Cell Targeted Therapies in Autoimmune Cytopenias and Thrombosis,penic purpura. This chapter presents a historical perspective reviewing the various studies that have been published in this field. In addition, it offers a current assessment of the evidence regarding the use of B-cell depleting agents in the aforementioned conditions.作者: 捕鯨魚叉 時間: 2025-3-30 18:02
Targeting B Cells in Neurological Autoimmune Diseases,etrospective, and with a few exceptions, e.g. MS, randomized controlled trials are lacking. In this article, we review and discuss the available literature on B cell-targeted therapies in autoimmune neurologic diseases.作者: Chandelier 時間: 2025-3-30 23:53
2296-6056 n for scientists, clinicians and pharmaceutical companies.Im.This book provides a detailed overview of B-cell directed therapies in patients with rheumatic and systemic autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, Sj?gren syndrome, ANCA-associated vasculitis and
